Alpine Immune Sciences, Inc. (ALPN) Comparison with companies in other sectors?

Alpine Immune Sciences, Inc. has a share price of 68.60M. You can analyze Alpine Immune Sciences, Inc. (ALPN) competitors across different market sectors through stock heatmaps.

What are ALPN's NET and operating margins?

Alpine Immune Sciences, Inc. (ALPN) operating margin is around -0.56, and net profit margin is approximately -0.32 as of the latest reports.

In what way does ALPN's earnings per share (EPS) trend reflect its financial momentum?

Alpine Immune Sciences, Inc. (ALPN) EPS is -0.64 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Alpine Immune Sciences, Inc. is -101.52, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Alpine Immune Sciences, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Alpine Immune Sciences, Inc. like P/E which is -347.90, P/B which is 12.50, and PEG which is 44.53. Compare them with sector averages to evaluate if the stock is priced fairly.

Alpine Immune Sciences, Inc.

ALPN•NASDAQ

Healthcare

Biotechnology

$64.97

$0.01(0.02%)

Alpine Immune Sciences, Inc. (ALPN) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.64

P/E Ratio

-101.52

ROE

-0.04%

Net Margin

-0.32%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$4.46B

Shares OutstandingTotal number of shares issued

$68.60M

Book Value/ShareNet worth per share

$5.20

Revenue/ShareAnnual revenue per share

$0.59

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.64

Net MarginNet income as percentage of revenue

-31.56%

Operating MarginOperating income as percentage of revenue

-55.82%

ROEReturn on shareholders' equity

-3.62%

ROAReturn on total assets

-3.20%

ROCEReturn on capital employed

-6.19%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.73

Cash/ShareCash and equivalents per share

$4.77

FCF YieldFree cash flow as percentage of market cap

-1.05%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ALPNFinancial Ratios Analysis details for ALPN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ALPNSector Benchmarking details for ALPN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Alpine Immune Sciences, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Alpine Immune Sciences, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Alpine Immune Sciences, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Alpine Immune Sciences, Inc.

For Alpine Immune Sciences, Inc., essential financial indicators include EPS -0.64, PE -101.52, and ROE -0.04. These key ratios reveal insights into Alpine Immune Sciences, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Alpine Immune Sciences, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Alpine Immune Sciences, Inc.

Metrics like Net Margin -31.56% and ROA -3.20% shed light on how well Alpine Immune Sciences, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Alpine Immune Sciences, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Alpine Immune Sciences, Inc.

Using ratios such as P/B Ratio 12.50 and PEG Ratio 44.53, investors can assess whether Alpine Immune Sciences, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Alpine Immune Sciences, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Alpine Immune Sciences, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.03 and Cash Flow $-0.73, provide a snapshot of Alpine Immune Sciences, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Alpine Immune Sciences, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Alpine Immune Sciences, Inc.

Investing in Alpine Immune Sciences, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Alpine Immune Sciences, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;